2-Chlorodeoxyadenosine Treatment of Refractory Chronic Lymphocytic Leukemia
- 1 January 1991
- journal article
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 5 (sup1), 133-138
- https://doi.org/10.3109/10428199109103394
Abstract
Ninety patients with advanced refractory chronic lymphocytic leukemia (CLL) were treated with 2-chlorodeoxyadenosine (2-CdA) administered either as a 0.1 mg/kg/day 7-day continuous intravenous infusion or as a 0.028 mg to 0.14 mg/kg/day 2-hour bolus for 5 consecutive days. One patient had stage A disease, seven patients had stage B disease, and 82 patients had stage C disease. Twenty-seven patients were female and 63 were male, with an age range of 40 to 84 years, median 63 years. All patients had received prior therapy and failed, with a range of one to four and a median of two prior therapies. Six patients had previously failed fludarabine therapy. Four patients (4%) experienced complete remissions, and 40 patients (40%) experienced partial remissions, yielding an over all response rate of 44%. The median duration of response was four months, with a range of two to 30 months. Of 50 patients who were non-responders, 27 (54%) had a greater than 50% sustained reduction in the absolute lymphocyte count despite insufficient improvement in hemoglobin concentration or platelet count to achieve a response status. Therapy was well tolerated with myelosuppression being the principal toxicity. Twenty-two patients (24%) experienced thrombocytopenia and 16 patients (18%) had documented infections. We confirm our early pilot results with 2-CdA demonstrating in a large group of patients that 2-CdA achieves a significant response rate with two different drug administration schemes in failed CLL patients. Responses are achieved with acceptable toxicity. 2-CdA merits further evaluation in previously untreated patients and in combination regimens for failed patients.Keywords
This publication has 8 references indexed in Scilit:
- Fludarabine: a new agent with major activity against chronic lymphocytic leukemiaBlood, 1989
- Pentostatin in chronic lymphocytic leukemia: a phase II trial of Cancer and Leukemia group B.Journal of Clinical Oncology, 1989
- Chronic Lymphocytic Leukemia: Recommendations for Diagnosis, Staging, and Response CriteriaAnnals of Internal Medicine, 1989
- Guidelines for clinical protocols for chronic lymphocytic leukemia: Recommendations of the national cancer institute‐sponsored working groupAmerican Journal of Hematology, 1988
- 2-Chlorodeoxyadenosine: an effective new agent for the treatment of chronic lymphocytic leukemiaBlood, 1988
- Platelet-associated and plasma anti-glycoprotein autoantibodies in chronic ITPBlood, 1987
- Antileukemic and immunosuppressive activity of 2-chloro-2'-deoxyadenosine.Proceedings of the National Academy of Sciences, 1984
- Specific toxicity of 2-chlorodeoxyadenosine toward resting and proliferating human lymphocytesBlood, 1983